The Entecavir Trial for Pediatric Patients with Chronic Hepatitis B Virus Infection who are HBeAg Positive is a comparative, randomized, double-blinded, placebo-control, multicenter study. The study is assessing the efficacy and safety of Entecavir (Baraclude) in pediatric subjects with chronic HBV infection who are HBeAg-positive and have not received previous treatment with a nucleos(t)ide therapy.
Eligible subjects will be between the age of 2 and < 18 years of age at time of enrollment. After concluding the treatment phase of the study, all subjects will be followed in an observational long-term follow up phase until they complete a total of five years of study participation.
CHOP’s Biesecker Pediatric Liver Center is an active participant in this research.